GSK3 inhibitors enhance retinoic acid receptor activity and induce the differentiation of retinoic acid-sensitive myeloid leukemia cells.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed.

1. Retinoic Acid Supplementation Rescues the Social Deficits inFrontiers in genetics · 2022
   Article
2. GSK-3: a multifaceted player in acute leukemias.Leukemia · 2021
   Review
3. Salt-inducible kinase inhibition sensitizes human acute myeloid leukemia cells to all-trans retinoic acid-induced differentiation.International journal of hematology · 2021
   Article
4. Phase I Trial of Lithium and Tretinoin for Treatment of Relapsed and Refractory Non-promyelocytic Acute Myeloid Leukemia.Frontiers in oncology · 2020
   Article
5. The Roles of GSK-3β in Regulation of Retinoid Signaling and Sorafenib Treatment Response in Hepatocellular Carcinoma.Theranostics · 2020
   Article
6. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma.Blood · 2019
   Article
7. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia.Science translational medicine · 2018
   Article
8. Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017
   Review
9. RRD-251 enhances all-trans retinoic acid (RA)-induced differentiation of HL-60 myeloblastic leukemia cells.Oncotarget · 2016
   Article
10. A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity.Molecular cancer therapeutics · 2016
    Article
11. GSK-3 Inhibition Sensitizes Acute Myeloid Leukemia Cells to 1,25D-Mediated Differentiation.Cancer research · 2016
    Article
12. Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016
    Article
13. Lithium chloride antileukemic activity in acute promyelocytic leukemia is GSK-3 and MEK/ERK dependent.Leukemia · 2015
    Article
14. Induction of autophagy is a key component of all-trans-retinoic acid-induced differentiation in leukemia cells and a potential target for pharmacologic modulation.Experimental hematology · 2015
    Article
15. An ATRActive future for differentiation therapy in AML.Blood reviews · 2015
    Article
16. Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.Leukemia · 2014
    Review
17. Molecular mechanisms responsible for the reduced expression of cholesterol transporters from macrophages by low-dose endotoxin.Arteriosclerosis, thrombosis, and vascular biology · 2013
    Article
18. GSK3 is a regulator of RAR-mediated differentiation.Leukemia · 2012
    Article
19. Retinoid differentiation therapy for common types of acute myeloid leukemia.Leukemia research and treatment · 2012
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as